ReGen Biologics Inc. (PINK:RGBO) rebuffed an offer from the FDA for one last go-around about the revocation of clearance for its Menaflex knee implant, saying it will try other ways of getting the device to the U.S. market.
The ever-feisty company, in an unusually long press release, said the six-year imbroglio with the federal watchdog agency “makes it clear that any such hearing would be futile.”